Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
N Engl J Med ; 385(12): 1067-1077, 2021 09 16.
Article Dans Anglais | MEDLINE | ID: covidwho-1413249

Résumé

BACKGROUND: Salt substitutes with reduced sodium levels and increased potassium levels have been shown to lower blood pressure, but their effects on cardiovascular and safety outcomes are uncertain. METHODS: We conducted an open-label, cluster-randomized trial involving persons from 600 villages in rural China. The participants had a history of stroke or were 60 years of age or older and had high blood pressure. The villages were randomly assigned in a 1:1 ratio to the intervention group, in which the participants used a salt substitute (75% sodium chloride and 25% potassium chloride by mass), or to the control group, in which the participants continued to use regular salt (100% sodium chloride). The primary outcome was stroke, the secondary outcomes were major adverse cardiovascular events and death from any cause, and the safety outcome was clinical hyperkalemia. RESULTS: A total of 20,995 persons were enrolled in the trial. The mean age of the participants was 65.4 years, and 49.5% were female, 72.6% had a history of stroke, and 88.4% a history of hypertension. The mean duration of follow-up was 4.74 years. The rate of stroke was lower with the salt substitute than with regular salt (29.14 events vs. 33.65 events per 1000 person-years; rate ratio, 0.86; 95% confidence interval [CI], 0.77 to 0.96; P = 0.006), as were the rates of major cardiovascular events (49.09 events vs. 56.29 events per 1000 person-years; rate ratio, 0.87; 95% CI, 0.80 to 0.94; P<0.001) and death (39.28 events vs. 44.61 events per 1000 person-years; rate ratio, 0.88; 95% CI, 0.82 to 0.95; P<0.001). The rate of serious adverse events attributed to hyperkalemia was not significantly higher with the salt substitute than with regular salt (3.35 events vs. 3.30 events per 1000 person-years; rate ratio, 1.04; 95% CI, 0.80 to 1.37; P = 0.76). CONCLUSIONS: Among persons who had a history of stroke or were 60 years of age or older and had high blood pressure, the rates of stroke, major cardiovascular events, and death from any cause were lower with the salt substitute than with regular salt. (Funded by the National Health and Medical Research Council of Australia; SSaSS ClinicalTrials.gov number, NCT02092090.).


Sujets)
Maladies cardiovasculaires/prévention et contrôle , Régime pauvre en sel , Hypertension artérielle/diétothérapie , Accident vasculaire cérébral/prévention et contrôle , Sujet âgé , Maladies cardiovasculaires/épidémiologie , Chine , Régime pauvre en sel/effets indésirables , Femelle , Humains , Hyperkaliémie/complications , Hypertension artérielle/complications , Hypertension artérielle/épidémiologie , Mâle , Adulte d'âge moyen , Mortalité , Potassium alimentaire/effets indésirables , Prévention secondaire , Accident vasculaire cérébral/épidémiologie
2.
Am Heart J ; 226: 198-205, 2020 08.
Article Dans Anglais | MEDLINE | ID: covidwho-645275

Résumé

BACKGROUND: High sodium intake has been considered as the leading dietary risk factor for deaths and disability-adjusted life-years among older adults. High-quality randomized trials to evaluate the effects of practical sodium reduction strategies are needed. METHODS: The study is a cluster randomized trial with a 2 × 2 factorial design conducted in 48 senior residential facilities in northern China. These facilities are randomly assigned (1:1:1:1) to 1 of 4 groups: stepwise salt supply control (SSSC) in which 5%-10% of the study salt supply in the institutional kitchens will be reduced every 3 months, replacing normal salt with salt substitute (SS); SSSC only; SS only; or neither SSSC nor SS. The interventions last for 2 years with follow-up every 6 months. The primary outcome is the change in systolic blood pressure from baseline to 24 months. Secondary outcomes include the incidence of hyperkalemia, hyponatremia, cardiovascular events, and death. CURRENT STATUS: The study has recruited and randomized 48 senior residential facilities with 1,606 participants. Mean age at baseline was 71 years, and 76% are male. Both types of salt intervention were initiated in the study facilities between January and April 2018. CONCLUSION: The study is well placed to define the effects of 2 practical and scalable sodium reduction strategies for blood pressure reduction and will provide important new data about safety of these strategies among older adults in China.


Sujets)
Pression sanguine/effets des médicaments et des substances chimiques , Pression sanguine/physiologie , Régime pauvre en sel/méthodes , Aromatisants/pharmacologie , Essais contrôlés randomisés comme sujet/méthodes , Chlorure de sodium alimentaire/pharmacologie , Sujet âgé , Femelle , Maisons de retraite médicalisées , Humains , Mâle
SÉLECTION CITATIONS
Détails de la recherche